[go: up one dir, main page]

ZA200906516B - Novel human anti-R7V antibodies and uses thereof - Google Patents

Novel human anti-R7V antibodies and uses thereof

Info

Publication number
ZA200906516B
ZA200906516B ZA200906516A ZA200906516A ZA200906516B ZA 200906516 B ZA200906516 B ZA 200906516B ZA 200906516 A ZA200906516 A ZA 200906516A ZA 200906516 A ZA200906516 A ZA 200906516A ZA 200906516 B ZA200906516 B ZA 200906516B
Authority
ZA
South Africa
Prior art keywords
antibodies
human anti
novel human
novel
human
Prior art date
Application number
ZA200906516A
Other languages
English (en)
Inventor
Jean-Claude Chermann
Camille Haslin
Original Assignee
Urrma R & D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39473318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200906516(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urrma R & D filed Critical Urrma R & D
Publication of ZA200906516B publication Critical patent/ZA200906516B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200906516A 2007-03-22 2009-09-18 Novel human anti-R7V antibodies and uses thereof ZA200906516B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89635907P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
ZA200906516B true ZA200906516B (en) 2010-05-26

Family

ID=39473318

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906516A ZA200906516B (en) 2007-03-22 2009-09-18 Novel human anti-R7V antibodies and uses thereof

Country Status (18)

Country Link
US (1) US20110123536A1 (xx)
EP (1) EP2137214A1 (xx)
JP (1) JP2010521189A (xx)
KR (1) KR20100014495A (xx)
CN (1) CN101679515A (xx)
AR (1) AR066396A1 (xx)
AU (1) AU2008228246A1 (xx)
BR (1) BRPI0808287A2 (xx)
CA (1) CA2681130A1 (xx)
CL (1) CL2008000820A1 (xx)
IL (1) IL201034A0 (xx)
MA (1) MA31256B1 (xx)
MX (1) MX2009009982A (xx)
RU (1) RU2009138922A (xx)
TN (1) TN2009000380A1 (xx)
TW (1) TW200846363A (xx)
WO (1) WO2008113833A1 (xx)
ZA (1) ZA200906516B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
ES2729945T3 (es) * 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
CN105020678B (zh) * 2015-08-04 2017-10-13 珠海金晟照明科技有限公司 透镜单元、透镜组件和路灯灯头
EP3455251A4 (en) 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai WIDE NEUTRALIZING HUMAN ANTI-CYTOMEGALOVIRUS ANTIBODIES AND METHODS OF USE
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019191079A1 (en) * 2018-03-26 2019-10-03 The University Of Chicago Methods and compositions for targeting liver and lymph node sinusoidal endothelial cell c-type lectin (lsectin)
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
US20230374114A1 (en) * 2020-04-16 2023-11-23 Dana-Farber Cancer Institute, Inc. Coronavirus antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS

Also Published As

Publication number Publication date
JP2010521189A (ja) 2010-06-24
CA2681130A1 (en) 2008-09-25
KR20100014495A (ko) 2010-02-10
EP2137214A1 (en) 2009-12-30
AR066396A1 (es) 2009-08-19
RU2009138922A (ru) 2011-04-27
IL201034A0 (en) 2010-05-17
AU2008228246A1 (en) 2008-09-25
MA31256B1 (fr) 2010-03-01
CN101679515A (zh) 2010-03-24
WO2008113833A1 (en) 2008-09-25
MX2009009982A (es) 2010-03-04
US20110123536A1 (en) 2011-05-26
TN2009000380A1 (en) 2010-12-31
BRPI0808287A2 (pt) 2014-10-07
TW200846363A (en) 2008-12-01
CL2008000820A1 (es) 2008-08-22

Similar Documents

Publication Publication Date Title
IL205866A0 (en) Antibodies against human nkg2d and uses thereof
IL211684A0 (en) Antibodies against human il 17 and uses thereof
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
ZA201003025B (en) Anti-hepcidin antibodies and uses thereof
LT2436696T (lt) Anti-beta-amiloido antikūnas ir jo panaudojimas
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
EP2097534A4 (en) HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
IL216731A (en) And antibodies against p95 – her2 and their uses
IL201156A0 (en) ANTI-IgE ANTIBODIES AND USES THEREOF
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
IL201020A0 (en) C5 antigens and uses thereof
HUE044595T2 (hu) Humán IL-22 elleni ellenanyagok és alkalmazásuk
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL236237A (en) Tmem154 antibodies and their segments and uses
EP2193144A4 (en) ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF
GB0812277D0 (en) Antibody and uses thereof
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
ZA200905136B (en) Anti-robo4 antibodies and uses therefor
HU0700758D0 (en) The basic of biocomputer and the possible realization thereof
GB0506945D0 (en) Human antibodies
GB0503190D0 (en) Human antibodies